Near infrared enhanced palladium loaded siraitia grosvenorii carbon dots amplify mitophagy for acute lung injury immunotherapy.

Zhang J, Duan K, Liu Q, Chen S, Zheng H, Liu Y, Qian J, Yin M, Liu J, Li J, Li Z, Chen M and 4 more

Show all authors

Huang X, Lin F, Gao M, Liao L

Bioactive materials4 Mar 2026Cited by 2 (Europe PMC)

PMID41810016PMCIDPMC12969342DOI10.1016/j.bioactmat.2026.02.040PepBankPUB-41810016

Read at source PubMedAsk about this study

Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study9

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone9

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

01AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
CPs@SS31 plus near-infrared irradiation increased the number of CD4+ T cells.
In plain wordsIn lab or animal tests, a carbon-dot construct carrying SS31 with infrared light raised CD4+ T cell numbers.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseCD4+ T cell number
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
upregulated CD4⁺ T cells number and CD4⁺/CD8⁺ ratio
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4181001606
02AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
CPs@SS31 plus near-infrared irradiation increased the CD4+/CD8+ ratio.
In plain wordsIn lab or animal tests, a carbon-dot construct carrying SS31 with infrared light raised the CD4+/CD8+ T cell ratio.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseCD4+/CD8+ ratio
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
upregulated CD4⁺ T cells number and CD4⁺/CD8⁺ ratio
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4181001607
03AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In vitro and in vivo studies showed that CPs@SS31 alleviated lung inflammation in rats with acute lung injury.
In plain wordsIn rats with acute lung injury, a carbon-dot construct carrying SS31 reduced lung inflammation.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseLung inflammation
Study
ratn: not reported in source
acute lung injury
Outcome group
Inflammation markers · Respiratory
Source sentences
Summary
In vitro and in vivo studies both demonstrated the robust alleviated lung inflammation, and accelerated lung tissue repair in ALI rats models.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4181001608
04AnimalNot a test of Elamipretide (SS-31) aloneAnimal study (in vivo)Efficacy outcome
In vitro and in vivo studies showed that CPs@SS31 accelerated lung tissue repair in rats with acute lung injury.
In plain wordsIn rats with acute lung injury, a carbon-dot construct carrying SS31 sped up lung tissue repair.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseLung tissue repair
Study
ratn: not reported in source
acute lung injury
Outcome group
Wound healing · Respiratory
Source sentences
Summary
In vitro and in vivo studies both demonstrated the robust alleviated lung inflammation, and accelerated lung tissue repair in ALI rats models.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4181001609
05LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
CPs@SS31 (carbon dots with SS31) plus near-infrared irradiation scavenged reactive oxygen species, giving antioxidant and anti-inflammatory effects.
In plain wordsIn lab tests, a carbon-dot construct carrying SS31 with infrared light cleared reactive oxygen species.
Peptide
Elamipretide (SS-31)
Outcome
DecreaseROS scavenging
Study
n: not reported in source
Outcome group
Inflammation markers · Respiratory
Source sentences
Summary
CPs@SS31 combining with near infrared (NIR) irradiation not only directly scavenged reactive oxygen species to achieve antioxidant and anti-inflammation
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4181001601
06LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Mechanism
CPs@SS31 plus near-infrared irradiation amplified mitophagy by activating the PINK1/Parkin pathway.
In plain wordsIn lab tests, a carbon-dot construct carrying SS31 with infrared light boosted removal of damaged mitochondria.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseMitophagy via PINK1/Parkin
Study
n: not reported in source
Outcome group
Mitochondrial function · Respiratory
Source sentences
Summary
amplified mitophagy via activating PINK1/Parkin pathway
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4181001602
07LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
CPs@SS31 targeted mitochondria and increased ATP production in lipopolysaccharide-induced cells.
In plain wordsIn cells, a carbon-dot construct carrying SS31 raised ATP production in cells stressed with lipopolysaccharide.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseATP production
Study
n: not reported in source
LPS-induced cells
Outcome group
Mitochondrial function · Respiratory
Source sentences
Summary
it specifically targeted mitochondria to increase ATP production and mitochondrial membrane potential, thereby repairing the mitochondrial function of lipopolysaccharide induced cells
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4181001603
08LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
CPs@SS31 increased mitochondrial membrane potential in lipopolysaccharide-induced cells.
In plain wordsIn cells, a carbon-dot construct carrying SS31 raised mitochondrial membrane potential in cells stressed with lipopolysaccharide.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseMitochondrial membrane potential
Study
n: not reported in source
LPS-induced cells
Outcome group
Mitochondrial function · Respiratory
Source sentences
Summary
it specifically targeted mitochondria to increase ATP production and mitochondrial membrane potential, thereby repairing the mitochondrial function of lipopolysaccharide induced cells
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4181001604
09LabNot a test of Elamipretide (SS-31) aloneIn vitro (cells)Efficacy outcome
CPs@SS31 plus near-infrared irradiation efficiently induced macrophage M2 polarization.
In plain wordsIn lab tests, a carbon-dot construct carrying SS31 with infrared light pushed macrophages toward the M2 type.
Peptide
Elamipretide (SS-31)
Outcome
IncreaseMacrophage M2 polarization
Study
n: not reported in source
Outcome group
Immune response · Immune and inflammation
Source sentences
Summary
CPs@SS31+NIR efficiently induced macrophage M2 polarization, and upregulated CD4⁺ T cells number and CD4⁺/CD8⁺ ratio, thereby activating immunoregulation, and achieving ALI repair therapy.
In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).
Report a problemFND-4181001605

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
10 Oct 2026, 08:19 UTC
Study results updated
Version 1
9 Oct 2026, 02:47 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.